# A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease

> **NCT07132983** · PHASE2 · COMPLETED · sponsor: **Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA** · enrollment: 33 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Ensifentrine 3 mg
- **DRUG:** Glycopyrrolate 42.5 mcg
- **DRUG:** Ensifentrine 1.5 mg
- **DRUG:** Ensifentrine 3 mg (marketed formulation)

## Key facts

- **NCT ID:** NCT07132983
- **Lead sponsor:** Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-10-06
- **Primary completion:** 2025-11-28
- **Final completion:** 2025-11-28
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07132983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07132983, "A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07132983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*